Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Predominance of the heterozygous CCR5 delta-24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface.

Arendt V, Amand M, Iserentant G, Lemaire M, Masquelier C, Ndayisaba GF, Verhofstede C, Karita E, Allen S, Chevigné A, Schmit JC, Bercoff DP, Seguin-Devaux C.

J Int AIDS Soc. 2019 Sep;22(9):e25384. doi: 10.1002/jia2.25384.

2.

HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs.

De Scheerder MA, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, Rutsaert S, Verhofstede C, Kerre T, Malfait T, Hemelsoet D, Coppens M, Dhondt A, De Looze D, Vermassen F, Lemey P, Palmer S, Vandekerckhove L.

Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7. doi: 10.1016/j.chom.2019.08.003. Epub 2019 Aug 27.

PMID:
31471273
3.

Comparison of Sanger sequencing for hepatitis C virus genotyping with a commercial line probe assay in a tertiary hospital.

Goletti S, Zuyten S, Goeminne L, Verhofstede C, Rodriguez-Villalobos H, Bodeus M, Stärkel P, Horsmans Y, Kabamba-Mukadi B.

BMC Infect Dis. 2019 Aug 22;19(1):738. doi: 10.1186/s12879-019-4386-4.

4.

Piloting a surveillance system for HIV drug resistance in the European Union.

van de Laar MJ, Bosman A, Pharris A, Andersson E, Assoumou L, Ay E, Bannert N, Bartmeyer B, Brady M, Chaix ML, Descamps D, Dauwe K, Fonager J, Hauser A, Lunar M, Mezei M, Neary M, Poljak M, van Sighem A, Verhofstede C, Amato-Gauci AJ, Broberg EK.

Euro Surveill. 2019 May;24(19). doi: 10.2807/1560-7917.ES.2019.24.19.1800390.

5.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

6.

Quantification of total HIV-1 DNA in buffy coat cells, feasibility and potential added value for clinical follow-up of HIV-1 infected patients on ART.

Mortier V, Demecheleer E, Staelens D, Schauvliege M, Dauwe K, Dinakis S, Hebberecht L, Vancoillie L, Verhofstede C.

J Clin Virol. 2018 Sep;106:58-63. doi: 10.1016/j.jcv.2018.07.008. Epub 2018 Jul 26.

7.

Frequency of occurrence of HIV-1 dual infection in a Belgian MSM population.

Hebberecht L, Vancoillie L, Schauvliege M, Staelens D, Dauwe K, Mortier V, Verhofstede C.

PLoS One. 2018 Apr 6;13(4):e0195679. doi: 10.1371/journal.pone.0195679. eCollection 2018.

8.

Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities.

Verhofstede C, Dauwe K, Fransen K, Van Laethem K, Van den Wijngaert S, Ruelle J, Delforge ML, Vancutsem E, Vaira D, Stoffels K, Ribas SG, Dessilly G, Debaisieux L, Pierard D, Van Ranst M, Hayette MP, Deblonde J, Sasse A, Van Beckhoven D, Mortier V.

Infect Genet Evol. 2018 Jul;61:36-44. doi: 10.1016/j.meegid.2018.03.002. Epub 2018 Mar 6.

9.

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.

Verhofstede C, Fransen K, Van Den Heuvel A, Van Laethem K, Ruelle J, Vancutsem E, Stoffels K, Van den Wijngaert S, Delforge ML, Vaira D, Hebberecht L, Schauvliege M, Mortier V, Dauwe K, Callens S.

BMC Infect Dis. 2017 Nov 29;17(1):738. doi: 10.1186/s12879-017-2850-6.

10.

Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.

Mortier V, Vancoillie L, Dauwe K, Staelens D, Demecheleer E, Schauvliege M, Dinakis S, Van Maerken T, Dessilly G, Ruelle J, Verhofstede C.

Antivir Ther. 2018;23(3):277-281. doi: 10.3851/IMP3203.

PMID:
29063859
11.

A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium.

Vinken L, Fransen K, Pineda-Peña AC, Alexiev I, Balotta C, Debaisieux L, Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sonnerborg A, Vancutsem E, Van den Wijngaert S, Van Ranst M, Verhofstede C, Vandamme AM, Lemey P, Van Laethem K.

Virus Evol. 2017 Mar 5;3(Suppl 1). pii: vew036.020. doi: 10.1093/ve/vew036.020. eCollection 2017 Mar. No abstract available.

12.

Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus.

Vancoillie L, Hebberecht L, Dauwe K, Demecheleer E, Dinakis S, Vaneechoutte D, Mortier V, Verhofstede C.

Virology. 2017 Oct;510:185-193. doi: 10.1016/j.virol.2017.07.010. Epub 2017 Jul 24.

13.

Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma.

Lopes Dos Santos Santiago G, Brusselle G, Dauwe K, Deschaght P, Verhofstede C, Vaneechoutte D, Deschepper E, Jordens P, Joos G, Vaneechoutte M.

BMC Microbiol. 2017 May 10;17(1):109. doi: 10.1186/s12866-017-1022-6.

14.

Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation.

Dauwe K, Staelens D, Vancoillie L, Mortier V, Verhofstede C.

J Clin Microbiol. 2016 Jun;54(6):1605-1615. doi: 10.1128/JCM.00030-16. Epub 2016 Apr 13.

15.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

16.

Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate.

Dauwe K, Mortier V, Schauvliege M, Van Den Heuvel A, Fransen K, Servais JY, Bercoff DP, Seguin-Devaux C, Verhofstede C.

BMC Infect Dis. 2015 Nov 16;15:524. doi: 10.1186/s12879-015-1217-0.

17.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants.

Van Beckhoven D, Florence E, Ruelle J, Deblonde J, Verhofstede C, Callens S, Vancutsem E, Lacor P, Demeester R, Goffard JC, Sasse A; BREACH Belgian Research on AIDS and HIV Consortium.

BMC Infect Dis. 2015 Nov 3;15:496. doi: 10.1186/s12879-015-1230-3.

18.

Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.

Malatinkova E, De Spiegelaere W, Bonczkowski P, Kiselinova M, Vervisch K, Trypsteen W, Johnson M, Verhofstede C, de Looze D, Murray C, Kinloch-de Loes S, Vandekerckhove L.

Elife. 2015 Oct 6;4:e09115. doi: 10.7554/eLife.09115.

19.

HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.

Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L.

J Antimicrob Chemother. 2015 Dec;70(12):3311-6. doi: 10.1093/jac/dkv250. Epub 2015 Aug 31.

PMID:
26324076
20.

Late presentation to HIV testing is overestimated when based on the consensus definition.

Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D, Deblonde J, Delforge ML, Fransen K, Goffard JC, Legrand JC, Moutschen M, Piérard D, Ruelle J, Vaira D, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C; Belgian Research AIDS & HIV Consortium (BREACH).

HIV Med. 2016 Mar;17(3):231-4. doi: 10.1111/hiv.12292. Epub 2015 Jul 28.

21.

Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.

Vancoillie L, Mortier V, Demecheleer E, Schauvliege M, Vandekerckhove L, Vogelaers D, Verhofstede C.

Antivir Ther. 2015;20(8):789-94. doi: 10.3851/IMP2966. Epub 2015 May 6.

PMID:
25945956
22.

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

De Spiegelaere W, Philippé J, Vervisch K, Verhofstede C, Malatinkova E, Kiselinova M, Trypsteen W, Bonczkowski P, Vogelaers D, Callens S, Ruelle J, Kabeya K, De Wit S, Van Acker P, Van Sandt V, Emonds MP, Coucke P, Sermijn E, Vandekerckhove L.

PLoS One. 2015 Apr 15;10(4):e0123525. doi: 10.1371/journal.pone.0123525. eCollection 2015.

23.

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.

Kiselinova M, Anna M, Malatinkova E, Vervish K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19823. doi: 10.7448/IAS.17.4.19823. eCollection 2014.

24.

Factors associated with the continuum of care of HIV-infected patients in Belgium.

Van Beckhoven D, Lacor P, Moutschen M, Piérard D, Sasse A, Vaira D, Van den Wijngaert S, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C, Verbrugge R, Demeester R, De Wit S, Florence E, Fransen K, Delforge ML, Goffard JC, Goubau P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19534. doi: 10.7448/IAS.17.4.19534. eCollection 2014.

25.

Determinants of adherence in a cohort of Belgian HIV patients: a pilot study.

Degroote S, Vogelaers D, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vancauwenberghe J, Vandijck D.

Acta Clin Belg. 2014 Apr;69(2):111-5. doi: 10.1179/0001551214Z.00000000035.

PMID:
24724750
26.

Antiretrovirals for HIV prevention: when should they be recommended?

Kiselinova M, De Spiegelaere W, Verhofstede C, Callens SF, Vandekerckhove L.

Expert Rev Anti Infect Ther. 2014 Apr;12(4):431-45. doi: 10.1586/14787210.2014.896739. Review.

PMID:
24621251
27.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.

J Clin Microbiol. 2014 Feb;52(2):517-23. doi: 10.1128/JCM.02461-13. Epub 2013 Dec 4.

28.

Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection.

Vancoillie L, Demecheleer E, Callens S, Vogelaers D, Vandekerckhove L, Mortier V, Verhofstede C.

J Antimicrob Chemother. 2014 Apr;69(4):1098-103. doi: 10.1093/jac/dkt484. Epub 2013 Dec 12.

PMID:
24335486
29.

Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study.

Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vandijck DM.

J Int AIDS Soc. 2013 Dec 12;16:18643. doi: 10.7448/IAS.16.1.18643.

30.

Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients.

Mortier V, Dauwe K, Vancoillie L, Staelens D, Van Wanzeele F, Vogelaers D, Vandekerckhove L, Chalmet K, Verhofstede C.

PLoS One. 2013 Nov 7;8(11):e80259. doi: 10.1371/journal.pone.0080259. eCollection 2013.

31.

Transmission network of an HIV type 1 strain with K103N in young Belgian patients from different risk groups.

Ruelle J, Ingels MG, Jnaoui K, Ausselet N, Vincent A, Sasse A, Verhofstede C, Goubau P.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1306-9. doi: 10.1089/AID.2013.0108. Epub 2013 Jun 26.

PMID:
23731270
32.

Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.

Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, Leroux-Roels G.

Vaccine. 2013 Aug 12;31(36):3739-46. doi: 10.1016/j.vaccine.2013.05.021. Epub 2013 May 21.

33.

HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, Verhofstede C, Lie Y, Seguin-Devaux C, Schmit JC, Bercoff DP.

PLoS One. 2013 May 8;8(5):e60566. doi: 10.1371/journal.pone.0060566. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/7c0b830d-e75d-4128-ab54-7d5ecfd99d19.

34.

Touchdown digital polymerase chain reaction for quantification of highly conserved sequences in the HIV-1 genome.

De Spiegelaere W, Malatinkova E, Kiselinova M, Bonczkowski P, Verhofstede C, Vogelaers D, Vandekerckhove L.

Anal Biochem. 2013 Aug 15;439(2):201-3. doi: 10.1016/j.ab.2013.04.024. Epub 2013 May 7.

PMID:
23664868
35.

Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression.

Messiaen P, De Spiegelaere W, Alcami J, Vervisch K, Van Acker P, Verhasselt B, Meuwissen P, Calonge E, Gonzalez N, Gutierrez-Rodero F, Rodriguez-Martín C, Sermijn E, Poppe B, Vogelaers D, Verhofstede C, Vandekerckhove L.

PLoS One. 2012;7(11):e50204. doi: 10.1371/journal.pone.0050204. Epub 2012 Nov 30.

36.

Correlation of coreceptor usage and disease progression.

Verhofstede C, Nijhuis M, Vandekerckhove L.

Curr Opin HIV AIDS. 2012 Sep;7(5):432-9. doi: 10.1097/COH.0b013e328356f6f2. Review.

PMID:
22871636
37.

Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients.

Messiaen P, Verhofstede C, Vandenbroucke I, Dinakis S, Van Eygen V, Thys K, Winters B, Aerssens J, Vogelaers D, Stuyver LJ, Vandekerckhove L.

Virology. 2012 Apr 25;426(1):7-11. doi: 10.1016/j.virol.2012.01.002. Epub 2012 Feb 4.

38.

Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.

Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, Vogelaers D, Vandekerckhove L, Plum J, Verhofstede C.

J Infect Dis. 2012 Jan 15;205(2):174-84. doi: 10.1093/infdis/jir714. Epub 2011 Dec 5.

PMID:
22147802
39.

Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.

Symons J, Vandekerckhove L, Paredes R, Verhofstede C, Bellido R, Demecheleer E, van Ham PM, van Lelyveld SF, Stam AJ, van Versendaal D, Nijhuis M, Wensing AM.

Clin Microbiol Infect. 2012 Jun;18(6):606-12. doi: 10.1111/j.1469-0691.2011.03631.x. Epub 2011 Sep 9.

40.

Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients.

Speeckaert R, Colebunders B, Boelaert JR, Brochez L, Van Acker J, Van Wanzeele F, Hemmer R, Speeckaert MM, Verhofstede C, De Buyzere M, Arendt V, Plum J, Delanghe JR.

Arch Dermatol Res. 2011 Dec;303(10):763-9. doi: 10.1007/s00403-011-1161-9. Epub 2011 Jul 12.

PMID:
21748360
41.

Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.

Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM.

HIV Med. 2011 Oct;12(9):544-52. doi: 10.1111/j.1468-1293.2011.00922.x. Epub 2011 Apr 25.

42.

European guidelines on the clinical management of HIV-1 tropism testing.

Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vézinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sönnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA; European Consensus Group on clinical management of tropism testing.

Lancet Infect Dis. 2011 May;11(5):394-407. doi: 10.1016/S1473-3099(10)70319-4. Epub 2011 Mar 21. Review.

PMID:
21429803
43.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

44.

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):590-6. doi: 10.1097/QAI.0b013e3181f5b3d1.

PMID:
20847699
45.

Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections.

Chalmet K, Staelens D, Blot S, Dinakis S, Pelgrom J, Plum J, Vogelaers D, Vandekerckhove L, Verhofstede C.

BMC Infect Dis. 2010 Sep 7;10:262. doi: 10.1186/1471-2334-10-262.

46.

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.

Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ.

AIDS Res Ther. 2010 Feb 15;7:4. doi: 10.1186/1742-6405-7-4.

47.

Viral load assay sensitivity and low level viremia in HAART treated HIV patients.

Verhofstede C, Van Wanzeele F, Reynaerts J, Mangelschots M, Plum J, Fransen K.

J Clin Virol. 2010 Apr;47(4):335-9. doi: 10.1016/j.jcv.2010.01.008. Epub 2010 Feb 6.

PMID:
20138803
48.

High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.

Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M.

AIDS. 2010 Mar 13;24(5):669-73. doi: 10.1097/QAD.0b013e32833160fa.

PMID:
19926962
49.

Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study.

Rouet F, Foulongne V, Viljoen J, Steegen K, Becquart P, Valéa D, Danaviah S, Segondy M, Verhofstede C, Van de Perre P; WHO/ANRS 1289 Kesho Bora Study Group.

J Virol Methods. 2010 Feb;163(2):253-7. doi: 10.1016/j.jviromet.2009.10.005. Epub 2009 Oct 27.

PMID:
19837114
50.

Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya.

Steegen K, Luchters S, Dauwe K, Reynaerts J, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C.

AIDS Res Ther. 2009 Jun 16;6:12. doi: 10.1186/1742-6405-6-12.

Supplemental Content

Loading ...
Support Center